Building Up a CMO Team as Your Company Evolves

Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles

Pfizer on Advancing Data Analysis Capabilities through A New EDC/CDMS Platform

Insights from Tufts CSDD into Evolving Trial Partnerships Models

ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma

Understanding the Immunological Effects of Radiopharmaceuticals

How J&J Is Integrating Patient Centricity Across the Enterprise

Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics

What to Expect at the 2026 IO360° Summit

CMOs Working Flexibly with Consultants and Fractional Expertise

Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs

How Patient Organizations are Bridging Patient Inclusivity Gaps at the Site-Level

How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost

How to Embed Clinical Research in Rural and Frontier Health Systems

Optimizing the Value Proposition in Small Companies with Limited Budgets

From the DPHARM 2024 Archives: Biogen Pilot on Using Vocal Biomarkers to Identify Potential Participants for Clinical Trials

Merck on Enhancing Trial Participation, Relevance, and Impact through Patient and Community Engagement

Ensuring Continuity in Patient Insights to Strengthen Medicine Development

Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy